The ALS Association and Focused Ultrasound Foundation have partnered to support a small pilot clinical study that will leverage focused ultrasound technology as part of a new ALS treatment approach. The study will be led by Agessandro Abrahao, M.D., an assistant professor of neurology at the University of Toronto and an associate scientist at Sunnybrook Research Institute.
The American Academy of Neurology, The ALS Association and the American Brain Foundation have awarded the 2024 Sheila Essey Award to Eva Feldman, M.D., Ph.D., from the University of Michigan. Throughout her distinguished career, Feldman has shed light on biological processes that drive ALS development and progression, paving the way for the development of new therapies, including two first-ever human clinical trials of intraspinal stem cell implantation (injection) therapy for ALS.
Partnership with leading US-based ALS patient advocacy group furthers myTomorrows’ mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options
On behalf of everyone living with ALS and their families, the ALS Association sent a letter this week to members of the House and Senate demonstrating our support for the passing of the ALS Better Care Act which will increase access to multidisciplinary care clinics for people living with ALS.
The ALS Association, the largest ALS organization in the world, and NuvoAir, the leading value-based specialty care provider for heart and lung conditions, announced their partnership to support virtual pulmonary care for people living with ALS and their caregivers.
On behalf of everyone living with ALS and their families, the ALS Association sent a letter to CVS Caremark asking company to reconsider its current policy regarding coverage of Relyvrio.
The ALS Association is deeply concerned and disappointed about the delay in FY24 government funding. ALS research needs to be funded and increased—NOW. People living with ALS cannot wait. We call upon policymakers to prioritize ALS research and swiftly appropriate the necessary funds to support innovative research initiatives, clinical trials and the development of potential treatments.
The U.S. District Court for the District of Columbia struck down a 2021 federal rule on Monday that allowed health insurers to not count drug manufacturer copay assistance towards a beneficiary’s out-of-pocket costs. The ALS Association is part of a coalition of patient advocacy organizations supporting the effort to end “copay accumulator” policies.